This previously little-known immunotherapy stock recently saw its shares soar nearly 249% — and its market value surge from $300 million to more than $1…
Considering the state of affairs right now, investors may be reluctant to buy expensive stocks. Thankfully, there’s penny stocks. As the author of today’s article…
This clinical-stage biopharmaceutical company focused on developing treatments for different kinds of cancers just recently launched an IPO, making it just the second IPO to…
While most of the attention in the biotech space is currently focused on companies working on potential vaccines for the novel coronavirus and treatments for…
The coronavirus pandemic has crushed stocks, but a handful of stocks could be poised to benefit – at least in the short-term – from the…